The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement
CompletedPhase 4NCT05023278
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Patients experience pain after their knee replacement surgery - and some may continue to experience persistent pain long after their knee replacement surgery. Traditional pain management strategies reply on pain medication such as opioids for pain control. However, these drugs do not work well for pain associated with movement or the the nerve pain (tingling, electrical sensations) after surgery. In addition, opioids are associated with significant side effects such as nausea, vomiting, respiratory depression, depression, cognitive dysfunction and risk of persistent opioid use. Neuropathic pain medications, such as venlafaxine are effective in managing nerve pain. Recent studies also support its potential role in acute pain management. Here, we propose a prospective randomized clinical trial 1) to evaluate the efficacy of Venlafaxine in reducing pain intensity and opioid consumption at post-operative day 1 (POD1) and 1- week after surgery, and 2) to examine whether the use of Venlafaxine will reduce the incidents of chronic postsurgical pain in TKA patients at 3-month time point.
Study details
- Official title
- The Use of Venlafaxine in Reducing Acute Post-Surgical Pain and Opioid Consumption in Primary Total Knee Replacement
- Interventions
- Drug: Venlafaxine 37.5 MG
- Drug: Placebo
- Sponsor
- University of California, San Francisco
- Collaborators
- Orthopedic Research and Education Foundation
- Start date
- 2021-05-10
- Primary completion
- 2025-02-28
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * adult (male and female) subjects aged 18 to 75, * English speaking, * are scheduled for primary total knee arthroplasty with planned spinal anesthesia with saphenous peripheral nerve block at the adductor canal. Exclusion Criteria: * general anesthesia, * hepatic \& renal failure, * history of diabetic peripheral neuropathic pain, * chronic opioid use, * concurrent use of antidepressants, triptans, and/or linezolid, * allergy to the study medications, * prior knee surgery, * BMI \> 40, * bleeding disorders, * history of recent falls, * concurrent benzodiazepine use.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05023278